Mochida Pharmaceutical Co., Ltd. (Head office: Shinjuku-ku, Tokyo, President: Naoyuki Mochida, hereinafter “Mochida”), Marubeni Pharmaceutical (Suzhou) Co., Ltd., a Chinese subsidiary of Marubeni Pharmaceuticals Co., Ltd. (Head office: Suzhou, Jiangsu Province, Chairman of the Board & CEO: Yoshitaka Koketsu, hereinafter “Marubeni Pharma”), and Meiji Seika Pharma Co., Ltd. (Head office: Chuo-ku, Tokyo, President: Toshiaki Nagasato, hereinafter “Meiji”) announced that Mochida obtained new drug approval from the China National Medical Products Administration (NMPA) on December 22, 2025 for EPADEL S® (product name in Japan: Epadel S900, development code: MND-21), a highly purified eicosapentaenoic acid (EPA) ethyl ester formulation developed in China by Mochida and Marubeni Pharma for the treatment of severe hypertriglyceridemia.
Mochida has entered into a distribution agreement with Meiji for the marketing of EPADEL S® in China. Following this approval, Mochida will supply the product to Meiji, which will distribute it through its affiliated partner in China, MAXMIND Bio-Technology (Hainan) Co., Ltd. In addition, Mochida will provide support, including the provision of information, to MAXMIND Bio-Technology (Hainan) Co., Ltd. through Meiji.
Mochida and Meiji have entered into a contract for the sale of Epadel in the ASEAN region, including Thailand and Vietnam, and Taiwan. As of today, Epadel is being sold in Thailand, and preparations are underway for its launch in Vietnam.
Going forward, Mochida, Meiji, and Marubeni Pharma will work together to deliver EPADEL S® to patients in China and contribute to improving their quality of life.
About Epadel
Epadel is a highly purified EPA ethyl ester formulation developed by Mochida as the world's first medical drug. The active pharmaceutical ingredient is supplied by Nissui Corporation, which has advanced EPA purification technology and the capacity for mass production. Since its launch in 1990, it has been taken by many patients, as the flagship drug of Mochida.
[References]
Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. (https://www.mochida.co.jp), has been committed to research and development of innovative pharmaceutical products since its establishment in 1913 thus providing distinctive medicines to the medical community. Currently, the core pharmaceutical business focuses its resources on the targeted areas of cardiovascular medicine, gastroenterology, obstetrics and gynecology, and psychiatry while also providing medicines for intractable diseases and generics including biosimilars, to meet medical needs.
Marubeni Pharmaceutical (Suzhou) Co., Ltd.
Marubeni Pharmaceutical (Suzhou) Co., Ltd. is a subsidiary of Marubeni Pharmaceutical (China) Co., Ltd., which is under Marubeni Pharmaceuticals Corporation (https://www.marubeni-pharma.com) in Japan, and has capabilities in clinical development, manufacturing, and sales. The company entering 22nd year of doing business in China, and now it manufactures and sells products in the areas of infectious diseases, cardiology, and CNS.
Meiji Seika Pharma Co., Ltd.
Meiji Seika Pharma, since it launched penicillin in 1946, has been providing efficacious and high-quality pharmaceutical products including therapeutics and vaccines for infectious diseases, therapeutics for central nervous system diseases and generic drugs, to meet various medical needs.
For more information, please visit https://www.meiji.com/global/pharmaceuticals/.
MAXMIND Bio-Technology (Hainan) Co., Ltd.
Maxmind Bio-Technology (Hainan) Co., Ltd. is a Chinese pharmaceutical company, established in 2013, vertically integrated RD, producition and marketing in China with an international outlook. Meiji has partnered with Maxmind in sales since 2021 and has been expanding the business of Meicelin and Miocamycin in China.
